Hamid Yousaif Qureshi: Japanese Scientists Develop Artificial Blood
Hamid Yousaif Qureshi, Expert in Medication Management and Patient-Centric Care, shared a post on LinkedIn:
“Researchers at Nara Medical University in Japan have been developing an experimental artificial blood substitute known as hemoglobin vesicles (HbV).
These are microscopic particles designed to carry oxygen in a way similar to red blood cells.
Each vesicle contains purified hemoglobin enclosed inside a lipid layer that functions like a simplified cell membrane.
One of the key advantages is compatibility. Natural blood must be carefully matched between donor and patient due to surface markers.
These vesicles do not carry those markers, meaning they could potentially be used across different blood types without matching.
Another major benefit is storage.
Donated blood typically lasts around 42 days, while these artificial vesicles can remain stable for much longer under controlled conditions.
This could make them useful in emergencies, disaster response, and areas where blood supply is limited.
However, this technology is still under development.
Natural blood performs many roles beyond oxygen transport, including clotting, immune response, and nutrient delivery.
Current versions of artificial blood are mainly designed to support oxygen delivery in specific situations.
Further research and clinical studies are ongoing to determine safety, effectiveness, and how this technology could be used in real-world medical care.
Source: Nara Medical University – research on hemoglobin vesicles.
Disclaimer: This content is for informational purposes only.
Courtesy:
MedStories.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia